The inflammatory landscape orchestrated by IL30 includes a wide range of immunomodulatory molecules, primarily cytokines, such as IL1, IL5, IL6, IL13 and IL17, which can shape the immune cell context and exert a variety of tumor-promoting functions [62], but also IL10 and IL4 both paradoxically endowed with pro- or anti-inflammatory effects depending on their sources, doses and timing of release, as well as the molecular and cellular environments [79, 80]. The gene discussed is IL13; the disease is neoplasm.